Skip to main content

Advertisement

ADVERTISEMENT

Volume 20 - Issue 10 - October, 2008

Feature

Original Contribution
10/08/2008

§Edo Kaluski, MD, £Karl Eugen Hauptmann, MD, *Ralf MuÃàller, MD, §Steve Tsai, MD,
§Marc Klapholz MD, *Eberhard Grube, MD


Author Affiliations: 
From the *Department of Cardiology, Helios Heart Center, Siegburg, Germany, the  §Department of Cardiology, University Medical Center and the University of Medicine and Dentistry, Newark, New Jersey; and the £Department of Cardiology Krankenhaus der Barmherzigen Brüder Trier, Germany 
Disclosures: Dr. Kaluski is a consultant to and stockholder in Inspire-MD. Professor Grube is a consultant to Inspire-MD.
Manuscript submitted February 22, 2008, provisional acceptance given May 12, 2008, manuscript accepted June 30, 2008.
Address for correspondence: Edo Kaluski MD, FACC, FESC, Director of Invasive Cardiology and Cardiac Catheterization Laboratories, University Hospital, University of Medicine and Dentistry of New Jersey, 185 South Orange Avenue, MSB I-538, Newark, NJ   07101.  E-mail: kalusked@umdnj.edu

§Edo Kaluski, MD, £Karl Eugen Hauptma...
ABSTRACT: MGuard is a bare-metal stent covered by an ultra-thin polymer mesh sleeve on its external surface, designed to reduce embolization during coronary, cerebrovascular and peripheral interventions. Aim. To evaluate the feasibility and...
ABSTRACT: MGuard is a bare-metal stent covered by an ultra-thin polymer mesh sleeve on its external surface, designed to reduce embolization during coronary, cerebrovascular and peripheral interventions. Aim. To evaluate the feasibility and...
ABSTRACT: MGuard is a bare-metal...
10/08/2008
Journal of Invasive Cardiology
Original Contribution
10/08/2008

David R. Ramsdale, MB, ChB, FRCP, MD, Archana Rao, MB, ChB, MRCP, MD, Omar Asghar, MB, ChB, MRCP,
Kathryn A. Ramsdale, BSc, MB, ChB, Ewan McKay, BSc, MB, ChB<p></p>

Author Affiliations:  From the Cardiothoracic Centre, Liverpool, United Kingdom.
The authors report no conflicts of interest regarding the content herein.
Manuscript submitted March 24, 2008, provisional acceptance given April 30, 2008, manuscript accepted July 21, 2008.
Address for correspondence: Dr. David R Ramsdale, Consultant Cardiologist, The Cardiothoracic Centre, Thomas Drive, Liverpool. L14 3PE. Email: David.Ramsdale@ctc.nhs.uk
 

David R. Ramsdale, MB, ChB, FRCP, MD,...
ABSTRACT: Background. We report the late outcomes in 411 consecutive patients undergoing drug-eluting stent (DES) implantation by a single operator between 2003–2006. Methods. Prospective registry with continuous follow up. Patients with...
ABSTRACT: Background. We report the late outcomes in 411 consecutive patients undergoing drug-eluting stent (DES) implantation by a single operator between 2003–2006. Methods. Prospective registry with continuous follow up. Patients with...
ABSTRACT: Background. We report...
10/08/2008
Journal of Invasive Cardiology

Insights

Commentary
10/08/2008

1Pranab Das, MD, 2Vikramjit Chokar, MD, 3Aravinda Nanjundappa, MD, RVT, 4Robert S. Dieter, MD, RVT

Author Affiliations: 

From the 1Division of Cardiovascular Medicine, University of Tennessee Health Sciences Center, Memphis, Tennessee, 2University of Wisconsin-Madison, Wisconsin, 3Department of Medicine and Surgery, West Virginia University, Charleston, West Virginia, and 4Department of Interventional Cardiology, Loyola University, Maywood, Illinois,
The authors report no conflicts of interest related to the content herein.
Address for correspondence: Pranab Das, MD, Assistant Professor, Division of Cardiovascular Medicine, University of Tennessee Health Sciences Center, Memphis, TN 38163. Email: pranabmonisha@aol.com
 

1Pranab Das, MD, 2Vikramjit Chokar, M...
Since the approval of the drug-eluting stents (DES) in April of 2003 by the U.S. Food and Drug Administration (FDA) and a year earlier in Europe, the rise of DES had been phenomenal, a feat rarely seen in contemporary medicine. With much...
Since the approval of the drug-eluting stents (DES) in April of 2003 by the U.S. Food and Drug Administration (FDA) and a year earlier in Europe, the rise of DES had been phenomenal, a feat rarely seen in contemporary medicine. With much...
Since the approval of the...
10/08/2008
Journal of Invasive Cardiology

Advertisement

Advertisement

Advertisement